AstraZeneca Plc (AstraZeneca) is a pharmaceutical company that focuses on the research, development, and commercialization of prescription medicines. The company focuses on therapeutic areas of oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

AstraZeneca is focused on advancing its research and development (R&D) initiatives. The company harnesses data and technology to accelerate scientific progress. AstraZeneca's R&D efforts are guided by its 5R Framework, which prioritizes quality over quantity, leading to significant improvements in drug discovery and development success rates. The company is committed to transformative science, investing in areas such as disease biology, next-generation therapeutics, and clinical innovation. AstraZeneca also collaborates extensively with academia, biotech companies, and industry peers to drive scientific breakthroughs and improve healthcare access. Other R&D focus areas include oncology, single-cell sequencing, cell therapy research, and AI-driven genomic technology. The R&D units of AstraZeneca comprise three therapy-focused organizations: Oncology R&D, Biopharmaceuticals R&D, and Rare Disease R&D. These units aim to discover and develop therapies through late-stage development, focusing on areas such as cancer, cardiovascular, renal, and metabolic diseases, respiratory and immunology, vaccines and immune therapies, and rare diseases. It also collaborates with scientists at leading institutions to understand diseases, discover potential new drugs, and accelerate drug development. Furthermore, AstraZeneca operates six global strategic R&D centers located in the UK, the US, Sweden, and China. As of December 2025, the company's pipeline comprised 118 new molecular entities or major life-cycle management (LCM) projects in Phase II and Phase III, four new molecular entities under review, and 21 new molecular entities in its late-stage pipeline. AstraZeneca has established major technology alliances with organizations such as Benevolent AI, AI Sweden, and the Cambridge Centre for AI in Medicine to enhance its R&D capabilities. In FY2025, the company spent US$14,232 million on its R&D activities, which as a percentage of revenue, stood at 24.2% and grew 4.8% YoY. As of December 2025, the company has published 718 manuscripts, with 135 in high-impact peer-reviewed journals. In FY2025, the company had one NME approvals, 97 regulatory events, and 38 pipeline progression events. It also had more than 1,200 collaborators globally.